Overview
I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health. Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients. I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients. The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Early identification of delayed-onset ADA deficiency: The case for expanded first-tier newborn screening
Journal Article Journal of Human Immunity · January 5, 2026 Standard newborn screening using T cell receptor excision circles (TRECs) failed to detect delayed-onset ADA deficiency in two cases. Retrospective mass spectrometry (MS/MS) analysis showed diagnostic deoxyadenosine elevation at birth. We advocate ... Full text CiteA Review of Adenosine Deaminase 2 (ADA2) as a Biomarker of Monocyte/Macrophage Activation.
Journal Article Curr Allergy Asthma Rep · January 3, 2026 PURPOSE OF REVIEW: Adenosine deaminase 2 (ADA2) is predominantly expressed by and secreted from activated monocytes and macrophages into plasma. This review explores the utility of ADA2 as a biomarker of monocyte/macrophage activation in a range of conditi ... Full text Link to item CiteDiagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants.
Journal Article Arthritis Rheumatol · October 28, 2025 OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnost ... Full text Link to item CiteRecent Grants
DAZ-304: A Long-term Extension Study of Dazodalibep in Participants with SS
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infec
Clinical TrialPrincipal Investigator · Awarded by X4 Pharmaceuticals · 2025 - 2029Deconstructing the molecular and cellular mechanisms of psoriatic arthritis pain by an improved animal model
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2028View All Grants